Kriya key facts
as of Oct 2026- Operator of a gene therapeutics company intended to design and develop gene therapies for diseases with underlying biology.
- Kriya is valued at approximately $870.0M as of Oct 2026 (last reported valuation).
- It has raised $940.5M; the latest was Later Stage VC ($320.8M) in Aug 2025.
- Notable investors include Alumni Ventures, Foresite Capital, Peter Thiel, Sabrina Hahn, Premji Invest — 25 tracked in total.
- Status: Privately Held (backing).
Kriya's last reported valuation, Jul 2023. Nothing priced has surfaced since.
- ·The complete investor list: 25 names
- ·Watch Kriya: the Monday email on marks, rounds and moves
Kriya funding rounds
No funding rounds for Kriya are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Kriya
25+Kriya valuation
Kriya's last reported valuation was $870 million in Jul 2023. No priced round, secondary trade or fund mark has surfaced since.
Kriya investors
25 investors are on record for Kriya, including Alumni Ventures, Foresite Capital, Peter Thiel and Sabrina Hahn. By type, the record holds 3 venture capital firms, 2 hedge funds and 2 private investors.
About Kriya
Operator of a gene therapeutics company intended to design and develop gene therapies for diseases with underlying biology. The company utilizes a vector design platform to enhance its capabilities in de novo construct design, targeted sequence modification and data analysis, enabling physicians to minimize immunogenicity and improve tissue specificity.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Founded
- 2019
- Employees
- 189
- Website
- kriyatherapeutics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.